ABBV vs ELV

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.